UNIQURE N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.455 USD | -2.30% |
|
-5.20% | -34.05% |
| Apr. 12 | Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director | CI |
| Apr. 02 | UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to uniQure N.V. EMG 2021. P...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
2024-04-28
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.267
EUR
Average target price
18.98
EUR
Spread / Average Target
+344.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.05% | 221M | |
| -2.25% | 104B | |
| +1.51% | 97.42B | |
| +0.79% | 22.2B | |
| -17.89% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.14% | 15.06B | |
| +4.30% | 13.98B | |
| +34.79% | 11.66B |
- Stock Market
- Equities
- QURE Stock
- News uniQure N.V.
- Transcript : uniQure N.V. - Shareholder/Analyst Call
